Urothelial Carcinoma Clinical Trials in Beijing, Beijing Municipality
9 recruitingBeijing, Beijing Municipality, China
Showing 1–9 of 9 trials
Recruiting
Phase 3
Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma
Urothelial Carcinoma
BeiGene420 enrolled46 locationsNCT03967977
Recruiting
Not Applicable
Nectin-4 Specific LMW PET Probe Imaging in Urothelial Carcinoma
Urothelial Carcinoma
Peking University Cancer Hospital & Institute20 enrolled1 locationNCT05321316
Recruiting
Phase 3
A Trial of SHR-A2102 With Adebrelimab in Locally Advanced or Metastatic Urothelial Carcinoma
Locally Advanced or Metastatic Urothelial Carcinoma
Suzhou Suncadia Biopharmaceuticals Co., Ltd.462 enrolled1 locationNCT07393542
Recruiting
Phase 2
A Clinical Study of the Efficacy and Safety of Disitamab Vedotin in Combination With Radiotherapy for the Adjuvant Treatment of HER2 Overexpressing UTUC Patients With High Risk Factors for Recurrence After Radical Surgery
Upper Urinary Tract Urothelial Carcinoma
Peking University First Hospital60 enrolled1 locationNCT06210490
Recruiting
Phase 3
A Phase III Study of SHR-A2102 Versus Investigator-selected Therapy in Advanced Urothelial Carcinoma
Advanced Urothelial Carcinoma
Shanghai Hengrui Pharmaceutical Co., Ltd.402 enrolled1 locationNCT06738251
Recruiting
A Multicenter Clinical Trial of Urine DNA Testing for Bladder Cancer in China
Urothelial CarcinomaBladder CancerUrocystitis+1 more
Creative Biosciences (Guangzhou) Co., Ltd.482 enrolled1 locationNCT05337189
Recruiting
Phase 1Phase 2
9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer
Advanced Urothelial Carcinoma
Mabwell (Shanghai) Bioscience Co., Ltd.100 enrolled1 locationNCT06079112
Recruiting
Phase 3
A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma
Urothelial CarcinomaHER2-expressing
RemeGen Co., Ltd.452 enrolled2 locationsNCT05302284
Recruiting
Phase 2
A Study of RC48-ADC Combined With Cadonilimab（AK104）in the Treatment of HER2-expression Locally Advanced or Metastatic Urothelial Carcinoma
Urothelial Carcinoma
Shanxi Province Cancer Hospital36 enrolled2 locationsNCT06178601